REGENXBIO’s (RGNX) “Buy” Rating Reiterated at Chardan Capital

Chardan Capital reissued their buy rating on shares of REGENXBIO (NASDAQ:RGNX) in a report issued on Thursday morning,Benzinga reports. Chardan Capital currently has a $52.00 target price on the biotechnology company’s stock.

RGNX has been the topic of a number of other research reports. Leerink Partners lifted their target price on REGENXBIO from $16.00 to $20.00 and gave the company an “outperform” rating in a research report on Monday, December 15th. Barclays assumed coverage on shares of REGENXBIO in a research note on Tuesday. They issued an “overweight” rating and a $37.00 price target on the stock. Stifel Nicolaus lifted their target price on shares of REGENXBIO from $40.00 to $45.00 and gave the company a “buy” rating in a report on Friday, December 19th. Weiss Ratings restated a “sell (d-)” rating on shares of REGENXBIO in a research note on Thursday, January 22nd. Finally, HC Wainwright restated a “buy” rating and set a $34.00 target price on shares of REGENXBIO in a report on Tuesday, October 7th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $30.00.

REGENXBIO Stock Down 3.8%

Shares of RGNX opened at $11.16 on Thursday. REGENXBIO has a 52-week low of $5.03 and a 52-week high of $16.19. The stock has a fifty day simple moving average of $13.72 and a two-hundred day simple moving average of $11.33. The company has a market capitalization of $564.92 million, a PE ratio of -3.22 and a beta of 1.07.

REGENXBIO (NASDAQ:RGNX) last issued its earnings results on Thursday, November 6th. The biotechnology company reported ($1.20) EPS for the quarter, topping analysts’ consensus estimates of ($1.38) by $0.18. The company had revenue of $29.73 million for the quarter, compared to the consensus estimate of $24.41 million. REGENXBIO had a negative net margin of 110.29% and a negative return on equity of 78.29%. As a group, equities analysts anticipate that REGENXBIO will post -4.84 earnings per share for the current fiscal year.

Institutional Trading of REGENXBIO

A number of institutional investors have recently bought and sold shares of the business. Jones Financial Companies Lllp raised its position in shares of REGENXBIO by 44.4% during the 3rd quarter. Jones Financial Companies Lllp now owns 4,133 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 1,270 shares in the last quarter. Profund Advisors LLC raised its holdings in REGENXBIO by 11.8% during the third quarter. Profund Advisors LLC now owns 14,444 shares of the biotechnology company’s stock worth $139,000 after purchasing an additional 1,523 shares in the last quarter. Pale Fire Capital SE raised its holdings in REGENXBIO by 7.7% during the second quarter. Pale Fire Capital SE now owns 27,846 shares of the biotechnology company’s stock worth $229,000 after purchasing an additional 2,000 shares in the last quarter. State of Alaska Department of Revenue acquired a new position in shares of REGENXBIO in the 3rd quarter valued at $25,000. Finally, Diversified Trust Co. boosted its holdings in shares of REGENXBIO by 24.3% in the 4th quarter. Diversified Trust Co. now owns 13,378 shares of the biotechnology company’s stock valued at $193,000 after buying an additional 2,615 shares in the last quarter. 88.08% of the stock is owned by hedge funds and other institutional investors.

REGENXBIO News Summary

Here are the key news stories impacting REGENXBIO this week:

• Positive Sentiment: Chardan Capital reaffirmed a “buy” on RGNX and set a $52 price target, signaling strong upside from current levels. Chardan Reaffirmation
• Neutral Sentiment: Zacks notes RGNX recently jumped on higher volume (a 5.4% move) but warns that recent downward earnings‑estimate revisions could limit near‑term upside; investors should watch subsequent analyst revisions. Zacks: Soars 5.4%
• Positive Sentiment: Leerink (reported by Yahoo Finance) called the earlier selloff “an overreaction” to the clinical hold, suggesting a recovery is possible if forthcoming safety data and disclosures calm investors. Leerink Commentary
• Negative Sentiment: The U.S. FDA placed clinical holds on RGX‑111 and RGX‑121 following identification of a tumor in a trial participant (disclosed in a Form 8‑K on Jan. 28), a direct driver of the recent sharp stock decline and operational uncertainty for those programs. FDA Clinical Hold / Form 8‑K
• Negative Sentiment: Multiple law firms (Levi & Korsinsky, Pomerantz) have launched investigations alleging potential disclosure gaps or securities claims tied to the FDA action, increasing legal and reputational risk. Levi & Korsinsky Investigation Pomerantz Investigation
• Negative Sentiment: Media coverage (Investing.com, AAII, MSN) documents a steep market reaction and broad selloff following the FDA notice; near‑term stock performance will hinge on company updates, the FDA’s path to lifting holds, and any further safety disclosures. Investing.com Coverage

About REGENXBIO

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.